UNASSIGNED: As numerous real-world studies have described patient outcomes following treatment with NMV/r, this systematic literature review provides a comprehensive summary of evidence on NMV/r effectiveness against hospitalization and mortality further organized by clinically meaningful categories, such as acute versus longer-term follow-up, age, underlying health conditions, and vaccination status, to help inform health care decision making.
METHODS: We searched Embase and PubMed (December 22, 2021-March 31, 2023) and congress abstracts (December 1, 2021-December 31, 2022) for reports describing NMV/r effectiveness.
UNASSIGNED: In total, 18 real-world studies met final selection criteria. The evidence showed that NMV/r significantly reduced postinfection risk of all-cause and COVID-19-related hospitalization and mortality in both acute (≤30 days) (21%-92%) and longer-term (>30 days) (1%-61%) follow-up. The reduction in postinfection risk was higher when treatment was received within 5 days of symptom onset. Real-world effectiveness of NMV/r treatment was observed regardless of age, underlying high-risk conditions, and vaccination status.
CONCLUSIONS: The systematic literature review findings demonstrated the effectiveness of NMV/r against hospitalization and mortality during the Omicron period among individuals at high risk of progression to severe COVID-19 disease.
■由于许多真实世界的研究描述了NMV/r治疗后的患者结果,这篇系统的文献综述提供了关于NMV/r对住院和死亡率的有效性的证据的全面总结,进一步按临床有意义的类别进行组织,如急性和长期随访,年龄,潜在的健康状况,和疫苗接种状况,帮助告知医疗保健决策。
方法:我们搜索了Embase和PubMed(2021年12月22日至2023年3月31日)和国会摘要(2021年12月1日至2022年12月31日),以获取描述NMV/r有效性的报告。
■总共,18项真实世界研究符合最终选择标准。证据表明,在急性(≤30天)(21%-92%)和长期(>30天)(1%-61%)随访中,NMV/r均显著降低感染后全因和COVID-19相关住院风险和死亡率。当在症状发作后5天内接受治疗时,感染后风险的降低更高。无论年龄如何,都观察到NMV/r治疗的真实世界有效性,潜在的高风险状况,和疫苗接种状况。
结论:系统文献综述结果表明,在Omicron期间,NMV/r对严重COVID-19疾病进展风险高的个体的住院和死亡率具有有效性。